Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by prophetoffactzon Dec 31, 2022 10:57am
111 Views
Post# 35198348

RE:RE:RE:RE:Midatech at $1.0475

RE:RE:RE:RE:Midatech at $1.0475"Hummm,,,,can anyone name a junior company which has issued over 1 Billion shares into the public markets that has actually made it in business down the road in reality??"

If Mei Mei was asked what is the bigger threat to the advancement of xB3 the number of shares outstanding or little cash to develop the science what would she say? Saltareli also said being part of a financially strong company was a selling point of this merger. Armistice Capital is also a successful fund and is willing to join. Cash matters in biotech. It matters a lot.

As for the dilution, 25% of biotech has had a market cap below the value of cash on its balance sheet in recent months and how many more biotech stocks traded just above cash? Science has literally been a liability in this environment for many. The industry is seeking strategic alternatives. It has been the worst biotech market in history. Concept stocks with no human data like xB3 that are potentially years from a proof of concept in humans, and with positive cashflow horizons perhaps 7-10 years into the future and competitors ahead of it are the worst hit. BTI is not alone by a long shot and given its debt situation it was a leveraged play on this catastrophic environment.

One of the biggest factors that has weighed on BTI's failure over the last ten years has arguably been that it has been radically undercapitalized. When has it ever had US$10-US$20 million on its balance sheet to push the science forward? This is biotech. BTI has lived hand-to-mouth financially with small financings and increasingly on debt, etc. It has not been in control of its own destiny. Maybe Rathjen should have only agreed to take the job if shareholders were willing to do a $15 million financing to address the issue that has long plagued the company. It has been said that Rathjen was forced to swear that she would never dilute. She was handcuffed financially from the start and then the 1-in-100 year pandemic struck with Putin not far behind. She was forced to depend on partners who operate in strict silence and can take many years to advance to clinic.




<< Previous
Bullboard Posts
Next >>